 Home > Medical News > Latest Medical News > Better than approved therapy Pfizer JAK1 inhibitor for eczema to reach phase 3 clinical endpoint

Better than approved therapy Pfizer JAK1 inhibitor for eczema to reach phase 3 clinical endpoint

 Last Update: 2021-09-13
 Source: Internet
 Author: User

Tags

group milan il

common cat diseases

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 30, 2021, Pfizer announced that the Phase 3 clinical trial of the oral JAK1 inhibitor abrocitinib, JADE DARE, has reached its common primary and critical secondary efficacy endpoints

Abrocitinib is an oral JAK1 inhibitor

The 26-week, randomized, double-blind, double-simulated, active-controlled, multi-center JADE DARE trial aims to compare the efficacy and safety of abrocitinib and approved IL-4Rα antibody therapy in the treatment of patients with atopic dermatitis

▲The molecular structure of Abrocitinib (picture source: Edgar181, Public domain, via Wikimedia Commons)

In terms of safety, the percentage of adverse events in the abrocitinib group was higher than that in the active control group

Atopic dermatitis is a chronic skin disease characterized by skin inflammation and skin barrier defects.

The complete results of JADE DARE will be submitted to future scientific conferences and published in medical journals

Reference materials:

[1] Positive Top-Line Results From Pfizer'S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.